Objective: This meta-analysis was conducted to summarize the association between an N-acetyltransferase 1 (NAT1) gene polymorphism and bladder cancer risk. Methods: PubMed Õ and EMBASE databases were searched to identify studies that examined the effect of the NAT1*10 allele on the risk of bladder cancer. Results: Eleven case-control studies, which included 3311 bladder cancer cases and 3906 control subjects, met the inclusion criteria. The pooled analyses based on all studies showed that there was no significant difference in the NAT1*10 allele between bladder cancer cases and controls (odds ratios [OR] 0.96; 95% confidence interval [CI] 0.81, 1.10). When stratifying for race, the results were similar among Caucasians (OR 0.96; 95% CI 0.81, 1.12) and Asians (OR 0.87; 95% CI 0.48, 1.56). No statistical association was found between the NAT1*10 allele and bladder cancer risk upon stratification for smoking status and study design. Conclusions: This meta-analysis suggests that there was no association between the NAT1*10 allele and bladder cancer risk. Further research should focus on other potentially functional genetic polymorphisms.
Introduction
Bladder cancer is one of the most common urological malignancies in the world, with an estimated 386,300 new cases and 150,200 deaths worldwide in 2008. 1 The highest incidence rates of bladder cancer are found in Europe, North America, and Northern Africa. 1 In European countries, there were an estimated 140,000 new cases of bladder cancer and 50,000 deaths from bladder cancer in 2008. 2 It is now commonly accepted that the cause of bladder cancer is a multifactorial interaction between environmental factors (e.g. exposure to certain chemicals, smoking and chronic urinary tract infections) and genetic susceptibility. [3] [4] [5] [6] [7] [8] [9] Arylamine N-acetyltransferase (NAT) has two isozymes, NAT1 and NAT2, which are encoded by the NAT1 and NAT2 genes, respectively. 10 Both of these genes are located on chromosome 8 and they have an open reading frame of 870 base pairs. 10 The NAT1 gene demonstrates genetic polymorphism in the 3 0 untranslated region; known polymorphic alleles are NAT1*4 (wild-type), NAT1*10, NAT1*11 and NAT1*3. 11 The NAT1*10 allele may increase enzyme activity. 12, 13 When the NAT1 genotype was compared with the NAT1 phenotype in bladder and colon tissue samples, an approximately twofold higher level of NAT1 enzyme activity was observed in samples taken from individuals who inherited a variant polyadenylation signal (NAT1*10 allele). 13 This was the first observation that linked a genetic polymorphism in the NAT1 gene to a particular level of N-acetylation activity in humans. 13 Several epidemiological studies have been published from different countries reporting on the association between the NAT1*10 allele and bladder cancer risk, 10,14-24 but there has been no systematic, quantitative assessment of the published findings on this topic. Therefore, this current meta-analysis of the published epidemiological studies was undertaken to clarify the effect of the NAT1*10 allele on the susceptibility to bladder cancer.
Materials and methods

Literature Search Strategy
A systematic search of publications listed in electronic databases (PubMed Õ and EMBASE) between January 1950 and August 2012 was conducted using the following key words: ('N-acetyltransferase' OR 'NAT') AND ('bladder' OR 'urinary' OR 'urocyst' OR 'urotheli*') AND ('adenocarcinoma*' OR 'carcinoma*' OR 'cancer*' OR 'tumour*' OR 'tumor*' OR 'neoplasm*'). Language restrictions were not applied. The list of articles was reviewed independently by two authors (K.W. and X.W.). The reference lists of the selected papers were screened manually for potentially relevant new articles. Furthermore, if more than one paper was published by an identical author using the same case series, the paper with the larger sample size was selected.
Study Selection
Criteria employed to select studies for this meta-analysis were as follows: (i) independent epidemiological studies (for humans only); (ii) a clear description of the NAT1 gene polymorphism in bladder cancer cases and control subjects. Exclusion criteria were: (i) not an original paper (e.g. review or letter); (ii) duplicate publications; (iii) no control subjects.
Data Extraction
Two investigators (K.W. and X.W.) independently extracted all the data from each study. Differences were resolved by a third investigator (Y.L.). The following data were extracted: first author's last name; publication year; country; study design; predominant racial composition of the study population; number of cancer cases and control subjects with different NAT1 genotypes; smoking status (never, light and heavy smokers) as defined by the individual studies.
Statistical Analyses
Statistical analyses were conducted Stata Õ software (version 11.0; Stata Corp., College Station, TX, USA). A fixed-or randomeffects model was used to calculate the pooled effect estimates depending on statistical heterogeneity. Statistical heterogeneity among the studies was tested with the Q ( 2test) and I 2 statistics (a P-value < 0.1 was taken to indicate a statistically significant level of heterogeneity). The crude odds ratios (ORs) were pooled using the random-effects model (DerSimonian and Laird method) when statistical heterogeneity was found (P < 0.1).
Subgroup analyses were performed on the basis of race, study design and smoking status. Publication bias was assessed by visual inspection of the funnel plots, the Begg's rank correlation method and the Egger's weighted regression method. 25, 26 A P < 0.05 was considered statistically significant, and all statistical tests were two sided.
Results
The initial review of the electronic databases identified 380 papers. Of these, 346 were excluded, leaving 34 studies for detailed review. Full text assessment resulted in the inclusion of 11 case-control studies in this current meta-analysis, which included 3311 bladder cancer cases and 3906 control subjects (Table 1) . 10, 14, 16, [18] [19] [20] [21] [22] [23] [24] The paper by McGrath et al. 20 was considered as two separate studies because it presents findings for the Nurses' Health Study and Health Professionals' Follow-up Study populations separately. Of the 11 studies, nine were hospital-based case-control (HCC) studies and two were nested case-control (NCC) studies. Ten studies reported on Caucasian populations and one reported on an Asian population. Studies were carried out in the USA, Italy, Poland, Germany, Spain, Denmark and China.
The pooled analyses (based on all studies) showed that there was no significant difference in the NAT1*10 allele between bladder cancer cases and control subjects (OR 0.96; 95% confidence interval [CI] 0.81, 1.10) ( Table 2 ) ( Figure 1 ). 10, 14, 16, [18] [19] [20] [21] [22] [23] [24] No statistically significant heterogeneity was observed for the overall test with the I 2 statistic (I 2 ¼ 0%; P ¼ 0.475) ( Table 2) . Furthermore, Begg's rank correlation method and Egger's weighted regression method found no evidence of publication bias in the studies (Begg's test, P ¼ 0.10; Egger's test, P ¼ 0.27).
When stratifying for race, results were similar among the Caucasian populations (OR 0.96; 95% CI ¼ 0.81, 1.12) and an Asian population (OR 0.87; 95% CI 0.48, 1.56) ( Table 2) . No statistically significant heterogeneity was observed with the I 2 statistic among Caucasians (P ¼ 0.39) ( Table 2) . Stratifying this meta-analysis by study design found no statistical association in the NCC studies (OR 0.96; 95% CI 0.56, 1.27) or HCC studies (OR 0.96; 95% CI 0.79, 1.14) ( Table 2) . No statistically significant heterogeneity was observed with the I 2 statistic in the NCC (P ¼ 0.41) or HCC studies (P ¼ 0.35) ( Table 2) .
Considering that smoking is a risk factor for bladder cancer and that the NAT1 gene is involved in the metabolism of various carcinogens present in smoke, 27 further analyses of a gene-dosage effect according to smoking status (never, light and heavy smokers) of participants were performed. Only four studies provided raw data for the NAT1*10 allele, smoking status and bladder cancer risk. 10, 18, 23, 24 Smoking did not modify the association between the NAT1*10 allele and bladder cancer risk in light (OR 1.32; 95% CI 0.83, 1.80) or heavy smokers (OR 0.83; 95% CI 0.26, 1.40) ( Table 2) . No statistically significant heterogeneity was observed with the I 2 statistic in light (P ¼ 0.75) or heavy smokers (P ¼ 0.13) ( Table 2 ).
Discussion
As a powerful statistical method, metaanalysis can help to summarize the effect size of the results from numerous Table 2 . Results of the meta-analysis of the relationship between polymorphisms in the arylamine N-acetyltransferase 1 gene (NAT1*10 allele) and susceptibility to bladder cancer in subgroups stratified according to race, study design and smoking status. 10 independent epidemiological studies, and thus provide more reliable outcomes. This current meta-analysis of 11 case-control studies, which included 3311 bladder cancer cases and 3906 control subjects, found no association between the NAT1*10 allele and bladder cancer risk.
There was also no association between the NAT1*10 allele and bladder cancer risk when stratifying for race, smoking status and study design. It has been concluded that current cigarette smokers have an approximately threefold higher risk of urinary tract cancer than nonsmokers. 27 In Europe, approximately half of urinary tract cancer cases among males, and one-third of cases among females, might be attributable to cigarette smoking. 27 Considering that smoking is a risk factor for bladder cancer and that the NAT1 gene is involved in the metabolism of various carcinogens present in smoke, 27 further analyses of a gene-dosage effect according to smoking status (never, light and heavy smokers) of subjects were performed.
Smoking did not modify the association between the NAT1*10 allele and bladder cancer risk in light or in heavy smokers. The apparent discrepancy between these findings could be explained as follows: (i) it has now become clear that gene-gene interactions and gene-environmental interactions are ubiquitous and fundamental mechanisms for the development of bladder cancer, but no genegene interactions were detected in this study; (ii) it was not possible to obtain information on the main confounders (environmental factors such as diet, occupational exposure to certain carcinogenic chemicals, drinking chlorinated water, arsenic exposure and exposure to hair dyes) from most of the studies; (iii) the definitions of the categories Figure 1 . Overall results of a meta-analysis of the relationship between polymorphisms in the arylamine N-acetyltransferase 1 gene (NAT1*10 allele) and susceptibility to bladder cancer. 10, 14, 16, [18] [19] [20] [21] [22] [23] [24] ID, identification; OR, odds ratio; CI, confidence interval. of never, light and heavy smokers were quite different between the studies, which may have contributed to a degree of heterogeneity that was not detected by the I 2 statistic in the pooled analysis. Therefore, this result regarding the impact of smoking status on the association between the NAT1*10 allele and bladder cancer risk should be interpreted with some caution.
This current meta-analysis has several limitations. First, in terms of the quality of the studies that were included in this metaanalysis, all were undertaken before the 'Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE Statement' report was published in 2009, which provides guidance on how to report transparently the findings of genetic association studies. 28 A number of studies included in the current meta-analysis did not meet all of the requirements of the STREGA recommendations. Secondly, it was not possible to perform an adjustment estimate because of the lack of individual patient data. Thirdly, because many environmental factors may affect bladder cancer susceptibility, all of the findings from this current meta-analysis might be due to the context of the genetic background and interactions with multiple environmental factors. Fourthly, the database for this current metaanalysis included limited numbers of studies on ethnic populations; only one study reported on an Asian population, reflecting the current lack of epidemiological studies in non-Caucasian populations. Finally, metaanalysis is just a statistical test that is subject to many methodological restrictions.
To our knowledge, this is the first metaanalysis to provide a quantitative summary of the evidence of the role of the NAT1*10 allele in bladder cancer risk, and the findings suggest that there is no association between the NAT1*10 allele and bladder cancer risk. Further research should focus on other potentially functional genetic polymorphisms.
Declaration of Conflicting Interest
